Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927389 | 1.00 | MME (0.73) | MMEANPEP | |
| SCHEMBL23752212 | 1.00 | MME (0.73) | MMEANPEP | |
| Bromide SCHEMBL6926898 | 0.99 | MME (0.72) | MMEANPEP | |
| Bromide SCHEMBL6928095 | 0.94 | MME (0.80) | MMEANPEP | |
| SCHEMBL12611280 | 0.89 | — | — | |
| SCHEMBL7615348 | 0.89 | — | — | |
| SCHEMBL30301323 | 0.88 | MME (0.62) | MMEANPEP | |
| Hydrochloric Acid SCHEMBL6928493 | 0.88 | — | — | |
| SCHEMBL12609418 | 0.87 | MME (0.71) | MMEANPEP | |
| SCHEMBL6927060 | 0.87 | MME (0.71) | MMEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291599-B2 | Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases | KEYNEUROTEK AG (DE) | 2007-11-06 | — | — | US | claimed |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2178527-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GmbH (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024348-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024348-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | ANPEP, DNPEP, RNPEP | MME 72/4885ANPEP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.